{
  "meta": {
    "title": "16_Chronic_Kidney_Disease",
    "url": "https://brainandscalpel.vercel.app/16-chronic-kidney-disease-d9cef44c.html",
    "scrapedAt": "2025-11-30T06:57:03.369Z"
  },
  "questions": [
    {
      "id": 74268,
      "choices": [
        {
          "id": 257319,
          "text": "Amyloidosis"
        },
        {
          "id": 257320,
          "text": "Diabetes. mellitus"
        },
        {
          "id": 257321,
          "text": "Rapidly progressive (crescentic) glomerulonephrtis"
        },
        {
          "id": 257322,
          "text": "Benign nephrosclerosis"
        }
      ],
      "text": "In which of the following conditions bilateral contracted kidneys are characteristically seen?",
      "unique_key": "Q7251286",
      "question_audio": null,
      "question_video": null,
      "map_id": 34335153,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Benign nephrosclerosis. Explanation: Benign nephrosclerosis is a condition often associated with chronic hypertension, leading to gradual and progressive kidney damage. Over time, this results in fibrosis and atrophy of the kidney parenchyma, causing the kidneys to shrink and become contracted. The bilateral contracted kidneys are a characteristic feature of this condition, with progressive scarring leading to reduced kidney size. This condition is commonly seen in elderly individuals with long-standing hypertension. Explanation for Incorrect Answers: A. Amyloidosis: Amyloidosis involves the deposition of amyloid proteins in various organs, including the kidneys. While this can lead to kidney dysfunction and even enlargement in some cases due to amyloid deposits, it is not typically associated with contracted kidneys. The kidneys in amyloidosis may appear enlarged and have a distinctive waxy appearance. B. Diabetes mellitus: In diabetes, chronic hyperglycemia leads to diabetic nephropathy, which initially presents with glomerular hyperfiltration and enlargement of the kidneys. Over time, however, if left untreated, diabetic nephropathy can lead to kidney damage and fibrosis, but it is not classically characterized by bilateral contracted kidneys at the onset. The kidney size may decrease later, but the initial presentation usually involves kidney enlargement due to hypertrophy of glomeruli. C. Rapidly progressive (crescentic) glomerulonephritis: Crescentic glomerulonephritis is an acute, often severe, renal condition characterized by the formation of crescents in the glomeruli. It causes rapid renal failure but does not typically lead to contracted kidneys early in the disease. The kidneys may appear swollen or normal-sized in the early stages, but progressive glomerular damage and fibrosis can eventually lead to scarring and shrinkage if the disease is not controlled. However, contracted kidneys are not a hallmark feature in the acute phase.",
      "correct_choice_id": 257322,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43111811698667540/43111811698667540.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43111811698667540/43111811698667540.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74269,
      "choices": [
        {
          "id": 257323,
          "text": "Osteoporosis"
        },
        {
          "id": 257324,
          "text": "Osteomalacia"
        },
        {
          "id": 257325,
          "text": "Adynamic Bone Disease"
        },
        {
          "id": 257326,
          "text": "Ostietis cystica fibrosa"
        }
      ],
      "text": "The most common Bone disease in CKI",
      "unique_key": "Q4037174",
      "question_audio": null,
      "question_video": null,
      "map_id": 34328584,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Osteitis fibrosa cystica. Explanation: In chronic kidney illness (CKD), osteitis fibrosa cystica is the most common bone disease and is directly related to secondary hyperparathyroidism. This condition occurs due to the kidneys' inability to excrete phosphate and activate vitamin D, leading to elevated parathyroid hormone (PTH) levels. Increased PTH causes bone resorption, which leads to the formation of cystic spaces in the bones and the development of fibrous tissue. This bone disease is a classic complication of CKD and is most commonly seen in advanced stages of kidney disease. Explanation for Incorrect Answers: A. Osteoporosis: Osteoporosis is characterized by decreased bone mineral density, making bones more fragile. While CKD can contribute to osteoporosis due to altered calcium and phosphate metabolism, osteitis fibrosa cystica is much more common in CKD and is related to the high levels of PTH and bone resorption. B. Osteomalacia: Osteomalacia is the softening of the bones due to vitamin D deficiency or impaired mineralization. While vitamin D deficiency can occur in CKD, the hallmark bone disease in CKD is more typically osteitis fibrosa cystica rather than osteomalacia. In CKD, low vitamin D levels contribute to secondary hyperparathyroidism rather than directly leading to osteomalacia. C. Adynamic Bone Disease: Adynamic bone disease refers to a condition where there is a decrease in bone turnover, leading to very low bone activity. It is associated with low parathyroid hormone (PTH) levels, often seen in patients with treated or well-managed CKD (especially with medications that lower PTH). While it occurs in CKD, osteitis fibrosa cystica is the most common bone disease seen in untreated or advanced CKD stages, where PTH levels remain high.",
      "correct_choice_id": 257326,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44142561698667590/44142561698667590.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44142561698667590/44142561698667590.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74270,
      "choices": [
        {
          "id": 257327,
          "text": "Normochromic"
        },
        {
          "id": 257328,
          "text": "Microcytic"
        },
        {
          "id": 257329,
          "text": "Macrocytic"
        },
        {
          "id": 257330,
          "text": "Hemolytic"
        }
      ],
      "text": "The most common form of Anaemia in CKI",
      "unique_key": "Q2845870",
      "question_audio": null,
      "question_video": null,
      "map_id": 34126469,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Normochromic. Explanation: The most common form of anemia in chronic kidney illness (CKD) is normochromic anemia, which is typically normocytic as well. This anemia is primarily due to reduced erythropoietin (EPO) production by the kidneys, which is necessary for red blood cell production in the bone marrow. In CKD, the kidneys' ability to produce EPO is impaired, leading to insufficient red blood cell production and, consequently, normocytic, normochromic anemia. This type of anemia is common in CKD due to both decreased EPO and the underlying chronic inflammation in the body. Explanation for Incorrect Answers: B. Microcytic: Microcytic anemia is usually associated with iron deficiency or thalassemia, but it is not the most common form in CKD. While iron deficiency can be seen in CKD due to poor absorption and chronic blood loss, the anemia typically presents as normocytic and normochromic, not microcytic. C. Macrocytic: Macrocytic anemia is typically seen in conditions like vitamin B12 or folate deficiency, or in liver disease, but it is not the most common type in CKD. While macrocytosis can occur in CKD, it is less frequent compared to normocytic anemia caused by erythropoietin deficiency. D. Hemolytic: Hemolytic anemia occurs when red blood cells are prematurely destroyed, leading to a low red blood cell count. It is not the most common form of anemia in CKD. While hemolysis can occur in certain CKD-related conditions (e.g., in patients with dialysis), normochromic anemia remains the predominant type.",
      "correct_choice_id": 257327,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66887411698667607/66887411698667607.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66887411698667607/66887411698667607.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74271,
      "choices": [
        {
          "id": 257331,
          "text": "Non-Compliance"
        },
        {
          "id": 257332,
          "text": "Untreated Iron deficiency"
        },
        {
          "id": 257333,
          "text": "Inadequate EPO dosage"
        },
        {
          "id": 257334,
          "text": "All of the above"
        }
      ],
      "text": "Anemia of advanced renal insufficiency is best treated by EPO injection. The causes of failure of EPO therapy include:",
      "unique_key": "Q8444245",
      "question_audio": null,
      "question_video": null,
      "map_id": 34592306,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Explanation: The failure of EPO (erythropoietin) therapy in the treatment of anemia in advanced renal insufficiency can occur due to several factors, including non-compliance, untreated iron deficiency, and inadequate EPO dosage. Non-compliance with the prescribed EPO injections can result in insufficient therapeutic effect. Untreated iron deficiency is a common cause of failure because iron is essential for red blood cell production, and without adequate iron stores, EPO therapy will not be effective. Additionally, inadequate EPO dosage may result in insufficient erythropoiesis, especially if the dose is too low to stimulate adequate red blood cell production. Therefore, all of these factors contribute to the failure of EPO therapy. Explanation for Incorrect Answers: A. Non-Compliance: Non-compliance can prevent the proper administration of EPO injections, leading to suboptimal treatment outcomes. However, it is only one of the causes of EPO therapy failure, not the only factor. B. Untreated Iron deficiency: Iron deficiency can interfere with the effectiveness of EPO therapy because iron is crucial for the production of hemoglobin in red blood cells. If iron levels are low, EPO treatment alone may not be sufficient to correct the anemia. This is an important cause of failure, but it is not the only one. C. Inadequate EPO dosage: Inadequate dosing of EPO may lead to insufficient stimulation of red blood cell production, which could cause a failure to correct anemia. However, this is just one possible reason for treatment failure, not the only cause.",
      "correct_choice_id": 257334,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50282771698667622/50282771698667622.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50282771698667622/50282771698667622.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74272,
      "choices": [
        {
          "id": 257335,
          "text": "Acute blood loss"
        },
        {
          "id": 257336,
          "text": "Chronic lymphocytic leukaemia"
        },
        {
          "id": 257337,
          "text": "EPO deficiency"
        },
        {
          "id": 257338,
          "text": "Sideroblastic anaemia"
        }
      ],
      "text": "A 44years old woman with Type 1 DM has not attended the diabetic clinic for 5 years. Her HbA1c is 10.1%. Examination shows no abnormality. Her Hb is 9.0g/dl, PCV 28%, MCV 94mcm3. A blood smear shows normocytic, normochromic anaemia. Which of the following is the most likely cause?",
      "unique_key": "Q2131776",
      "question_audio": null,
      "question_video": null,
      "map_id": 34909544,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) EPO deficiency. Explanation: In this case, the most likely cause of the patient's normocytic, normochromic anemia is EPO (erythropoietin) deficiency, which is commonly seen in patients with long-standing Type 1 diabetes mellitus. Over time, diabetes can lead to diabetic nephropathy, a condition that impairs the kidneys' ability to produce erythropoietin. Erythropoietin is a hormone necessary for stimulating red blood cell production in the bone marrow, and its deficiency leads to normocytic anemia (normal-sized red blood cells) with no evidence of iron deficiency or other abnormalities. The patient's HbA1c of 10.1% suggests poor long-term control of her diabetes, increasing the likelihood of kidney dysfunction and subsequent EPO deficiency. Explanation for Incorrect Answers: A. Acute blood loss: Acute blood loss typically leads to anemia with low hematocrit and hemoglobin levels, and often microcytic anemia (small red blood cells) is observed initially, especially if there is iron loss. The patient's Hb (9.0 g/dL) and normocytic anemia do not suggest acute blood loss as the cause. B. Chronic lymphocytic leukaemia (CLL): CLL can cause anemia due to bone marrow infiltration or autoimmune hemolysis. However, CLL usually presents with other symptoms such as lymphadenopathy, splenomegaly, or elevated white blood cell count. The absence of these features and the normocytic, normochromic anemia makes CLL an unlikely cause. D. Sideroblastic anaemia: Sideroblastic anemia is a type of microcytic anemia caused by impaired hemoglobin synthesis, often due to defects in the heme production pathway or iron metabolism. However, this patient's anemia is normocytic, not microcytic, and therefore sideroblastic anemia is unlikely.",
      "correct_choice_id": 257337,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1901851698667635/1901851698667635.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1901851698667635/1901851698667635.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74273,
      "choices": [
        {
          "id": 257339,
          "text": "Hypocalcaemia"
        },
        {
          "id": 257340,
          "text": "Hypercalcemia"
        },
        {
          "id": 257341,
          "text": "Hypophostaemia"
        },
        {
          "id": 257342,
          "text": "Hyerphosphatemia"
        }
      ],
      "text": "Renal osteodystrophy differs nutritional and genetic forms of osteomalacia in having:",
      "unique_key": "Q1619786",
      "question_audio": null,
      "question_video": null,
      "map_id": 34383951,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hyperphosphatemia. Explanation: Renal osteodystrophy, a bone disease associated with chronic kidney disease (CKD), is characterized by hyperphosphatemia due to impaired renal excretion of phosphate. In CKD, the kidneys lose their ability to filter and excrete phosphate, leading to its accumulation in the blood. Elevated phosphate levels result in secondary hyperparathyroidism, which further contributes to bone remodeling abnormalities and mineralization defects seen in renal osteodystrophy. This distinguishes it from nutritional and genetic forms of osteomalacia, which are primarily associated with hypocalcemia, hypophosphatemia, or vitamin D deficiency rather than hyperphosphatemia. Explanation for Incorrect Answers: A. Hypocalcaemia: Hypocalcemia is often seen in both renal osteodystrophy and nutritional/genetic forms of osteomalacia due to impaired vitamin D metabolism in CKD. However, it is not the distinguishing feature of renal osteodystrophy since it is also common in other types of osteomalacia. B. Hypercalcemia: Hypercalcemia is not typically seen in renal osteodystrophy unless there is overtreatment with calcium supplements or vitamin D analogs. Therefore, this is not a key feature distinguishing renal osteodystrophy from other forms of osteomalacia. C. Hypophosphatemia: Hypophosphatemia is characteristic of nutritional and genetic forms of osteomalacia, especially in cases involving vitamin D deficiency or phosphate-wasting syndromes. It is not seen in renal osteodystrophy, where phosphate levels are elevated due to impaired renal excretion.",
      "correct_choice_id": 257342,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29985561698667697/29985561698667697.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29985561698667697/29985561698667697.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74274,
      "choices": [
        {
          "id": 257343,
          "text": "Blood transfusions"
        },
        {
          "id": 257344,
          "text": "Recombinanthumanerythropoietin therapy"
        },
        {
          "id": 257345,
          "text": "Parenteral iron therapy"
        },
        {
          "id": 257346,
          "text": "Folic acid."
        }
      ],
      "text": "Anaemia of advanced renal insufficiency is best treated by:",
      "unique_key": "Q4691339",
      "question_audio": null,
      "question_video": null,
      "map_id": 34702559,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Recombinant human erythropoietin therapy. Explanation: Anemia in advanced renal insufficiency is primarily caused by erythropoietin (EPO) deficiency, as the damaged kidneys are unable to produce adequate levels of this hormone. Recombinant human erythropoietin (rHuEPO) therapy is the most effective treatment because it directly addresses the underlying cause of the anemia by stimulating erythropoiesis (red blood cell production) in the bone marrow. rHuEPO therapy significantly improves hemoglobin levels, reduces the need for blood transfusions, and enhances the quality of life in patients with chronic kidney disease (CKD). It is considered the gold standard for managing anemia in CKD. Explanation for Incorrect Answers: A. Blood transfusions: While blood transfusions can temporarily increase hemoglobin levels, they are not the preferred treatment for anemia in CKD. They carry risks such as iron overload, immune sensitization, and transmission of infections. Transfusions are reserved for severe anemia or in cases where rHuEPO therapy is ineffective or contraindicated. C. Parenteral iron therapy: Parenteral iron therapy is used to correct iron deficiency, which is a common cause of anemia in CKD and a frequent co-factor affecting the response to rHuEPO therapy. However, iron therapy alone is not sufficient to treat anemia due to EPO deficiency and is typically used in combination with rHuEPO if iron stores are low. D. Folic acid: Folic acid supplementation is important for managing anemia caused by folate deficiency, which is not the primary cause of anemia in advanced renal insufficiency. Folic acid has a limited role in CKD-related anemia unless there is a documented deficiency.",
      "correct_choice_id": 257344,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34051271698667707/34051271698667707.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34051271698667707/34051271698667707.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74275,
      "choices": [
        {
          "id": 257347,
          "text": "50%of normal"
        },
        {
          "id": 257348,
          "text": "25%of normal"
        },
        {
          "id": 257349,
          "text": "10-25% of normal"
        },
        {
          "id": 257350,
          "text": "5-10%of normal"
        }
      ],
      "text": "The term ‘end stage renal disease (ESRD)’ is considered appropriate when GFR falls to:",
      "unique_key": "Q5625727",
      "question_audio": null,
      "question_video": null,
      "map_id": 34148783,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) 5-10% of normal. Explanation: End-stage renal disease (ESRD) is a term used to describe the final stage of chronic kidney disease (CKD), when the kidneys have lost most of their ability to function. It is typically defined as a glomerular filtration rate (GFR) of 5-10% of normal, which indicates a severe reduction in kidney function. At this point, the kidneys can no longer maintain homeostasis, and dialysis or kidney transplantation becomes necessary to sustain life. When GFR falls to this level, the body experiences significant waste accumulation, fluid imbalance, and electrolyte disturbances, leading to life-threatening conditions. Explanation for Incorrect Answers: A. 50% of normal: A GFR of 50% of normal indicates moderate kidney dysfunction but is not considered ESRD. At this stage, kidney function is impaired, but the kidneys can still compensate for some loss. It is typically categorized as stage 3 CKD, not end-stage. B. 25% of normal: A GFR of 25% of normal indicates severe kidney impairment, but it is not yet ESRD. This level of kidney function corresponds to stage 4 CKD, where there is a marked decline in kidney function, but dialysis or transplantation is not necessarily required yet. ESRD occurs when kidney function is closer to 5-10% of normal. C. 10-25% of normal: A GFR between 10-25% of normal reflects stage 5 CKD, but ESRD is specifically defined when GFR falls to 5-10% of normal. While both options are related to advanced kidney failure, ESRD is considered at the lower end of this range, at 5-10% of normal.",
      "correct_choice_id": 257350,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24870981698668975/24870981698668975.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24870981698668975/24870981698668975.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74276,
      "choices": [
        {
          "id": 257351,
          "text": "Decreased anion gap"
        },
        {
          "id": 257352,
          "text": "Normal anion gap"
        },
        {
          "id": 257353,
          "text": "Increased anion gap"
        },
        {
          "id": 257354,
          "text": "Metabolic alkalosis"
        }
      ],
      "text": "In advanced stages of ‘chronic renal failure’ there is:",
      "unique_key": "Q1741722",
      "question_audio": null,
      "question_video": null,
      "map_id": 34190976,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Increased anion gap. Explanation: In advanced stages of chronic renal failure (CRF), there is a decreased ability of the kidneys to excrete acids, which leads to accumulation of unmeasured acids in the blood. This accumulation increases the anion gap, which is calculated as the difference between measured cations (sodium) and measured anions (chloride and bicarbonate). In CRF, the kidneys fail to excrete phosphate, sulfate, and organic acids properly, contributing to the buildup of acid in the blood. As a result, the anion gap increases, and patients may develop metabolic acidosis with an increased anion gap. Explanation for Incorrect Answers: A. Decreased anion gap: A decreased anion gap is not typically associated with chronic renal failure. A reduced anion gap can occur in conditions where there is an increase in unmeasured cations (e.g., hypoalbuminemia, lithium toxicity, or multiple myeloma). However, this is not a common finding in CRF, where an increased anion gap is the typical manifestation due to the retention of acids. B. Normal anion gap: In advanced CRF, the anion gap is usually increased rather than normal. Metabolic acidosis with an increased anion gap is a characteristic feature of chronic kidney disease (CKD) in its later stages due to the kidneys' inability to excrete acids adequately. A normal anion gap can be seen in other conditions like diarrhea or renal tubular acidosis (RTA), but it is not a feature of advanced renal failure. D. Metabolic alkalosis: Metabolic alkalosis is not typically seen in advanced chronic renal failure. In fact, metabolic acidosis is more common due to the kidney's reduced ability to eliminate hydrogen ions and reabsorb bicarbonate. Alkalosis might occur in some cases of CKD, but it is relatively rare and usually associated with other conditions (e.g., vomiting, diuretic use) rather than the renal failure itself.",
      "correct_choice_id": 257353,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10909481698668991/10909481698668991.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10909481698668991/10909481698668991.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74277,
      "choices": [
        {
          "id": 257355,
          "text": "Stage1"
        },
        {
          "id": 257356,
          "text": "Stage2"
        },
        {
          "id": 257357,
          "text": "Stage3"
        },
        {
          "id": 257358,
          "text": "Stage4"
        }
      ],
      "text": "A 40-year-old male with chronic kidney disease who weighs 70kg, has a serum creatinine value of 1.4mg/dl. What is the stage of his CKD:",
      "unique_key": "Q1251751",
      "question_audio": null,
      "question_video": null,
      "map_id": 34157445,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Stage 2. Explanation: Chronic Kidney Disease (CKD) stages are determined by the glomerular filtration rate (GFR), which is calculated based on serum creatinine levels, age, gender, and other factors. The stage of CKD is typically classified as follows: Stage 1: GFR ≥ 90 mL/min/1.73m² (with other evidence of kidney damage, such as proteinuria). Stage 2: GFR 60-89 mL/min/1.73m² (with kidney damage). Stage 3: GFR 30-59 mL/min/1.73m². Stage 4: GFR 15-29 mL/min/1.73m². Stage 5: GFR < 15 mL/min/1.73m² (or dialysis). In this case, the patient's serum creatinine is 1.4 mg/dL. Given that this serum creatinine level is not extremely high, we can estimate that the patient's GFR likely falls in the range of 60-89 mL/min/1.73m², which corresponds to Stage 2 CKD. This stage indicates mild kidney dysfunction, where kidney damage is present but the GFR is still relatively preserved. Explanation for Incorrect Answers: A. Stage 1: Stage 1 CKD requires a GFR ≥ 90 mL/min/1.73m², but the patient’s serum creatinine value suggests a GFR lower than this threshold. Therefore, Stage 1 is not applicable. C. Stage 3: Stage 3 CKD corresponds to a GFR of 30-59 mL/min/1.73m². Given the serum creatinine level of 1.4 mg/dL, the patient's GFR is likely above this range, making Stage 3 unlikely. D. Stage 4: Stage 4 CKD requires a GFR of 15-29 mL/min/1.73m², which is much lower than what would be expected with a serum creatinine of 1.4 mg/dL. Stage 4 is unlikely based on this information.",
      "correct_choice_id": 257356,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37387621698669281/37387621698669281.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37387621698669281/37387621698669281.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74278,
      "choices": [
        {
          "id": 257359,
          "text": "Observation with serial kidney function tests"
        },
        {
          "id": 257360,
          "text": "Increase anti Diabetes and antihypertensive drugs"
        },
        {
          "id": 257361,
          "text": "Immediate dialysis"
        },
        {
          "id": 257362,
          "text": "Renal transplant"
        }
      ],
      "text": "A 68-year-old man with a history of hypertension and diabetes who has had renal insufficiency for several years now comes to the OPD for evaluation of his kidneys. The patient is obese and has had difficulty controlling both his diabetes and high BP. He is adherent to diet and tries to exercise. Present Medications: Lisinopril, amlodipine, Sitagliptin, Gliclazide. On examination- Extremities: mild edema present, Chest: clear bilaterally, Cardiovascular: S4 gallop; no murmurs. BP: 150/96 mm Hg; Pulse: 64 beats/minute; serum creatinine 4 mg/dL; potassium 4.9 mEq/L; bicarbonate 22 mEq/L: urine dipstix- protein 2+,What will you do next.",
      "unique_key": "Q4682773",
      "question_audio": null,
      "question_video": null,
      "map_id": 34515272,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Increase anti-diabetes and antihypertensive drugs. This patient presents with chronic kidney disease (CKD), evidenced by elevated serum creatinine (4 mg/dL) and proteinuria (2+ on urine dipstick). His long-standing history of hypertension and diabetes, both poorly controlled, are major contributors to the development and progression of his CKD. The next step in management is to optimize his current therapies to better control both his diabetes and blood pressure, as these are crucial factors in slowing the progression of kidney disease. Specifically, tight glycemic control (through adjustments in Sitagliptin and Gliclazide) and more effective blood pressure control (by potentially adjusting or increasing his Lisinopril dose or adding additional antihypertensive agents) are key. Proper management of both conditions is associated with improved renal outcomes and reduced risk of progression to end-stage renal disease (ESRD). Incorrect Options: A. Observation with serial kidney function tests: Simply observing the patient without making adjustments to his diabetes and blood pressure management is insufficient. Serial kidney function tests might be useful for monitoring progression, but active intervention to control his hypertension and diabetes is needed. Given his elevated creatinine and proteinuria, without improving these underlying conditions, his kidney function will likely continue to deteriorate. Therefore, observation alone is not appropriate at this stage. C. Immediate dialysis: Dialysis is typically initiated when a patient is in end-stage renal disease (ESRD) with symptoms such as severe uremia (nausea, vomiting, confusion) or if other signs of life-threatening complications (like fluid overload or electrolyte imbalances) are present. In this case, the patient is not presenting with symptoms of acute kidney failure or uremic toxicity. His creatinine level (4 mg/dL) suggests chronic kidney insufficiency, but not yet ESRD. Immediate dialysis is premature in the absence of clinical indications for dialysis. D. Renal transplant: A renal transplant is a consideration in patients with end-stage renal disease who are experiencing severe kidney dysfunction and are not candidates for further conservative management. However, this patient is not yet in ESRD (based on his creatinine level and current clinical status). The focus should be on optimizing his current treatment regimen to delay progression to ESRD and potentially avoid the need for a transplant in the future.",
      "correct_choice_id": 257360,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57851401698821585/57851401698821585.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57851401698821585/57851401698821585.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74279,
      "choices": [
        {
          "id": 257363,
          "text": "Fatigue"
        },
        {
          "id": 257364,
          "text": "Pericarditis"
        },
        {
          "id": 257365,
          "text": "Refractory hyperkalemia"
        },
        {
          "id": 257366,
          "text": "Encephalopathy"
        }
      ],
      "text": "A 65-year-old patient with hypertension and chronic kidney disease for 20 years. He complaints of fatigue, weight loss, breathlessness on exertion and increasing sleepiness for last 1 month. On examination pallor +, extremity edema +, flapping tremors+, lungs-mild basal crepts, cardiovascular system- pericardial friction rub +. Lab results-Hb-8.0 g/dl,serum creatinine 7.0 mg/dl, BUN 150 mg/dl, serum K 7.0 mmol/L,pH-7.32,serum HCO3- 21 mmol/L,paCO2- 37 mmHg. You decided to plan for dialysis in the patient. Which of the patient’s manifestation not an indication for dialysis?",
      "unique_key": "Q3294084",
      "question_audio": null,
      "question_video": null,
      "map_id": 34160889,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Fatigue. This patient's symptoms, including fatigue, weight loss, breathlessness, increasing sleepiness, and physical examination findings such as pallor, edema, flapping tremors, and pericardial friction rub, suggest worsening chronic kidney disease (CKD) with acute decompensation. The manifestations of fatigue, although significant and affecting the patient's quality of life, do not typically require dialysis unless they are part of more severe complications of CKD, such as uremia or metabolic disturbances. Fatigue is a common symptom in patients with advanced kidney disease, but by itself, it is not an immediate indication for dialysis. Incorrect Options: B. Pericarditis: Pericarditis, specifically uremic pericarditis, is a well-known and life-threatening complication of advanced CKD. It occurs due to the buildup of uremic toxins in the bloodstream when the kidneys can no longer filter out waste effectively. Pericarditis is a strong indication for initiating dialysis, as it can lead to cardiac tamponade or arrhythmias, both of which can be fatal. Dialysis is indicated to treat the underlying uremic environment and relieve the pericarditis. C. Refractory hyperkalemia: Refractory hyperkalemia (potassium >6.5 mmol/L or symptoms) is a medical emergency and one of the classic indications for initiating dialysis. Elevated potassium levels can lead to cardiac arrhythmias and cardiac arrest. In this patient, the serum potassium level is 7.0 mmol/L, which is dangerously elevated. This condition requires urgent dialysis to remove excess potassium and prevent life-threatening arrhythmias. D. Encephalopathy: Uremic encephalopathy is another strong indication for dialysis. It occurs when uremic toxins accumulate in the body and affect the brain, leading to altered mental status, confusion, or even coma. In this patient, increasing sleepiness could be an early sign of uremic encephalopathy. If severe, it would warrant dialysis to correct the underlying uremia and improve neurological function.",
      "correct_choice_id": 257363,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21868801698821624/21868801698821624.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21868801698821624/21868801698821624.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74280,
      "choices": [
        {
          "id": 257367,
          "text": "Oral calcium supplement may be a risk factor"
        },
        {
          "id": 257368,
          "text": "This condition is due to calciphylaxis"
        },
        {
          "id": 257369,
          "text": "Warfarin is a risk factor for development of the lesion"
        },
        {
          "id": 257370,
          "text": "All the above"
        }
      ],
      "text": "A 63-year-old woman with chronic kidney disease is maintained on daily peritoneal dialysis. Her past medical history is notable for hypertension and atrial fibrillation. Her medications include losartan and warfarin. Two days ago, she noticed a small painful nodule on her abdomen that has progressed to involve skin necrosis and ulceration of the abdominal wall.<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/2(406).jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q4578562",
      "question_audio": null,
      "question_video": null,
      "map_id": 34946393,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) This is calciphylaxis-metastatic deposit of calcium phosphate in blood vessels causing blockage. The causes are secondary hyperparathyroidism, oral calcium and warfarin use. Warfarin decrease the vitamin K–dependent regeneration of matrix GLA protein. This GLA protein is important in preventing vascular calcification.",
      "correct_choice_id": 257370,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48245891698822305/48245891698822305.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48245891698822305/48245891698822305.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74281,
      "choices": [
        {
          "id": 257371,
          "text": "Start an erythropoietin-stimulating agent."
        },
        {
          "id": 257372,
          "text": "Transfuse packed red blood cells and start an erythropoietin-stimulating agent."
        },
        {
          "id": 257373,
          "text": "Start oral iron therapy."
        },
        {
          "id": 257374,
          "text": "Counsel the patient on vascular access for dialysis"
        }
      ],
      "text": "A 65-year-old woman with a history of stage 4 chronic kidney disease, hypertension, stroke, and recently diagnosed lung cancer presents to the clinic for evaluation of asymptomatic anemia. Hemoglobin is 10.5 g/dL. Iron stores are normal. Vitamin B12 and folate levels are found to be normal. What is the next step?",
      "unique_key": "Q8859017",
      "question_audio": null,
      "question_video": null,
      "map_id": 34215729,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Start an erythropoietin-stimulating agent. This 65-year-old woman with stage 4 chronic kidney disease (CKD) presents with asymptomatic anemia, a common finding in CKD due to decreased production of erythropoietin (EPO) by the kidneys. Since her iron stores, vitamin B12, and folate levels are normal, the anemia is likely related to renal anemia, which occurs due to insufficient erythropoietin production. The most appropriate next step is to initiate an erythropoietin-stimulating agent (ESA), such as epoetin alfa or darbepoetin alfa, to stimulate red blood cell production. This approach is commonly used in patients with CKD to manage anemia and improve their quality of life. Incorrect responses: B. Transfuse packed red blood cells and start an erythropoietin-stimulating agent.: This is incorrect. Blood transfusions are typically reserved for acute or severe anemia (hemoglobin < 7–8 g/dL or symptomatic anemia), which is not the case for this patient who is asymptomatic with a hemoglobin of 10.5 g/dL. In the absence of symptoms or extremely low hemoglobin, transfusion is not needed. The next step in this case is to start an erythropoietin-stimulating agent (ESA), as stated in the correct option. C. Start oral iron therapy.: This is incorrect. The patient's iron stores are normal, so there is no evidence of iron deficiency. Iron therapy is typically used when there is iron deficiency anemia, which is not the case here. Since the anemia is likely due to insufficient erythropoietin production related to CKD, the treatment should focus on erythropoietin-stimulating agents, not iron supplementation. D. Counsel the patient on vascular access for dialysis.: This is incorrect. The patient has stage 4 CKD, but there is no indication that she is near the need for dialysis at this point. Vascular access for dialysis is typically discussed when a patient progresses to stage 5 CKD (end-stage renal disease, ESRD), at which point dialysis would be necessary. This patient is still in stage 4, and the primary management focus should be on controlling the complications of CKD, such as anemia, through erythropoietin-stimulating agents.",
      "correct_choice_id": 257371,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5994961698822323/5994961698822323.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5994961698822323/5994961698822323.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74282,
      "choices": [
        {
          "id": 257375,
          "text": "Lower antihypertensive drug requirements"
        },
        {
          "id": 257376,
          "text": "Improved kidney function"
        },
        {
          "id": 257377,
          "text": "Reduced mortality"
        },
        {
          "id": 257378,
          "text": "All"
        }
      ],
      "text": "A 73-year-old man is identified as having a 70% stenosis of his right renal artery during CT angiography for abdominal pain. The left renal artery was normal. He has two-vessel coronary disease, for which stents were placed a month earlier. His cardiologist recommends that he undergo renal artery stenting after six months of clopidogrel therapy. He has hypertension for 15 years and now feels well. His current medications include an ACE inhibitor, a beta-blocker, an alpha-blocker, a diuretic, clopidogrel, and aspirin. BP: 146/74 mm Hg, Pulse: 65/min, Chest- Clear; No edema, Lab reports: CBC normal, Serum creatinine 1.4 mg/dL (eGFR: 49 mL/min/1.73 m2 ), sodium 140 mEq/L, potassium 4.6 mEq/L. Which of the following most accurately describes the likely results of renal artery stenting for this individual?",
      "unique_key": "Q6638320",
      "question_audio": null,
      "question_video": null,
      "map_id": 34721229,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Lower antihypertensive drug requirements Explanation: In this patient with renal artery stenosis (70% stenosis on CT angiography), renal artery stenting is a potential treatment option. The goal of stenting in patients with renal artery stenosis is to improve renal perfusion and correct renin-angiotensin-aldosterone system (RAAS) activation that often results from the reduced blood flow to the kidneys. This RAAS activation contributes to hypertension, and renal artery stenting can help reduce this effect. After successful stenting, the hypertension may improve, potentially leading to lower antihypertensive drug requirements. This is the most likely outcome for this patient, as stenting can improve blood flow to the kidney and decrease the need for multiple antihypertensive medications. Incorrect Responses: B. Improved kidney function: Although renal artery stenting can improve renal perfusion, kidney function improvement is not guaranteed in all patients, especially those with chronic kidney disease or long-standing hypertension. The patient already has an eGFR of 49 mL/min/1.73 m², indicating some degree of chronic kidney disease. While stenting may prevent further worsening of kidney function, it does not reverse existing damage or guarantee a significant improvement in eGFR. Therefore, improvement in kidney function is not the most likely outcome. C. Reduced mortality: There is limited evidence to suggest that renal artery stenting improves overall mortality in patients with isolated renal artery stenosis or hypertension. Studies have shown that stenting may improve blood pressure control and reduce the need for antihypertensive medications, but it does not consistently demonstrate a significant impact on overall mortality. Stenting is unlikely to result in a direct reduction in mortality for this patient, particularly considering his multiple comorbidities (e.g., coronary artery disease). D. All: While renal artery stenting may lead to lower antihypertensive drug requirements, it does not guarantee improved kidney function or a reduction in mortality. As discussed, these outcomes are not guaranteed or strongly supported by evidence, so \"all\" is not the most accurate choice.",
      "correct_choice_id": 257375,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8381841698824796/8381841698824796.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8381841698824796/8381841698824796.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74283,
      "choices": [
        {
          "id": 257379,
          "text": "Discontinue warfarin"
        },
        {
          "id": 257380,
          "text": "Start sodium thiosulfate"
        },
        {
          "id": 257381,
          "text": "Start vitamin K supplementation"
        },
        {
          "id": 257382,
          "text": "A +B"
        }
      ],
      "text": "A 56-year-old woman with ESRD on hemodialysis is evaluated for painful nodules on the abdomen which have been present for the past month. Medications include warfarin, metoprolol, atorvastatin, renal vitamin, calcium acetate. She is receiving calciferol and darbopoietin with dialysis. Physical examination reveals an overweight female with several hard, subcutaneous nodules approximately 1 cm in diameter in the lower abdomen; there is one open wound 1.5 cm in diameter with surrounding erythema. Laboratory studies reveal the following results: calcium 9.7 mg/dL; phosphate 6.0 mg/dL; PTH 550 pg/ mL. She undergoes a punch biopsy of the wound which shows findings consistent with calcific uremic arteriolopathy. Which of the following therapeutic approaches would you recommend?",
      "unique_key": "Q2659163",
      "question_audio": null,
      "question_video": null,
      "map_id": 34658232,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) A + B (Discontinue warfarin and start sodium thiosulfate) Explanation: This patient with end-stage renal disease (ESRD) and painful abdominal nodules is most likely suffering from calcific uremic arteriolopathy (CUA), a condition characterized by the calcification of small arteries and arterioles, leading to ischemic skin ulcers and painful nodules. It is a complication associated with chronic kidney disease and dysregulated mineral metabolism, which often leads to vascular calcifications. The management of CUA involves discontinuing warfarin, which can exacerbate vascular calcifications, and starting sodium thiosulfate, a treatment that has shown effectiveness in dissolving calcium deposits and preventing further progression of the disease. Incorrect Responses: A. Discontinue warfarin: While discontinuing warfarin is a key part of managing CUA, this option alone does not fully address the treatment. Warfarin can worsen vascular calcifications due to its effects on vitamin K-dependent proteins, which play a role in vascular calcification. Therefore, warfarin should be discontinued in this patient, but additional therapy is required. B. Start sodium thiosulfate: Sodium thiosulfate has been shown to help in the treatment of CUA, as it can dissolve calcium deposits and reduce skin ulcer formation. However, sodium thiosulfate alone will not address the potential exacerbating role of warfarin in this condition, which is why discontinuing warfarin is also essential. C. Start vitamin K supplementation: Vitamin K supplementation is not an appropriate treatment for calcific uremic arteriolopathy. In fact, increasing vitamin K may exacerbate vascular calcifications, as it supports the activity of vitamin K-dependent proteins like matrix Gla-protein that regulate calcification. Vitamin K supplementation could potentially worsen the condition, so it is not a recommended therapeutic approach.",
      "correct_choice_id": 257382,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36798331698824951/36798331698824951.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36798331698824951/36798331698824951.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74284,
      "choices": [
        {
          "id": 257383,
          "text": "Osteoporosis"
        },
        {
          "id": 257384,
          "text": "Osteomalacia"
        },
        {
          "id": 257385,
          "text": "Adynamic bone disease"
        },
        {
          "id": 257386,
          "text": "Osteitis cystica fibrosa"
        }
      ],
      "text": "A 35-year-old female is referred to you for evaluation of bone pain. She was completely well 2 years ago when she started developing intermittent aches and pains. Family history is non contributory. Laboratory values show the following: hemoglobin 12.8 g/ dL, MCV 85 fL, leukocyte and platelet count. Serum sodium, potassium, chloride, and bicarbonate are normal. Serum calcium is 9.2 mg/dL, phosphorus 2.0 mg/dL, alkaline phosphatase 350 U/L, 25-hydroxyvitamin D 22 ng/mL, and PTH 100 pg/mL. What is the likely cause?",
      "unique_key": "Q2574695",
      "question_audio": null,
      "question_video": null,
      "map_id": 34297396,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Osteomalacia Explanation: This 35-year-old woman presents with bone pain, low serum phosphorus (2.0 mg/dL), normal calcium (9.2 mg/dL), increased alkaline phosphatase (350 U/L), 25-hydroxyvitamin D deficiency (22 ng/mL), and elevated parathyroid hormone (PTH) levels (100 pg/mL). These findings are consistent with osteomalacia, a disorder characterized by defective bone mineralization due to vitamin D deficiency. In osteomalacia, despite normal calcium levels, the deficiency in vitamin D impairs the intestinal absorption of calcium and phosphorus, leading to secondary hyperparathyroidism (elevated PTH), which in turn increases bone turnover and alkaline phosphatase levels. The low phosphorus and increased alkaline phosphatase in the setting of vitamin D deficiency point directly to osteomalacia, where the bone matrix is soft, causing pain and other skeletal manifestations. Incorrect Responses: A. Osteoporosis: Osteoporosis is characterized by low bone mineral density (BMD) and an increased risk of fractures. While this patient's symptoms of bone pain could be due to osteoporosis, the key diagnostic features here, such as low phosphorus and vitamin D deficiency, suggest osteomalacia rather than osteoporosis. Osteoporosis generally does not cause changes in alkaline phosphatase or phosphorus levels, nor does it typically cause elevated PTH unless there is a secondary cause like renal dysfunction. Therefore, this patient’s findings do not support a diagnosis of osteoporosis. C. Adynamic bone disease: Adynamic bone disease typically occurs in the setting of chronic kidney disease (CKD) and is characterized by a low turnover of bone. In contrast to osteomalacia, which is a high-turnover bone disorder, adynamic bone disease results in insufficient bone remodeling. The patient's normal renal function, as evidenced by the normal electrolytes and creatinine levels, makes adynamic bone disease an unlikely diagnosis. Additionally, the elevated alkaline phosphatase in this case would not be seen in adynamic bone disease, where bone turnover is suppressed. D. Osteitis cystica fibrosa: Osteitis cystica fibrosa is a complication of hyperparathyroidism, often associated with chronic kidney disease and secondary hyperparathyroidism. While this patient has elevated PTH levels, she does not have the classic findings of osteitis cystica fibrosa, such as bone cysts or brown tumors on imaging. The low phosphorus and vitamin D deficiency are more suggestive of osteomalacia rather than osteitis cystica fibrosa, which typically results from more severe hyperparathyroidism often due to kidney dysfunction.",
      "correct_choice_id": 257384,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28578791698825075/28578791698825075.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28578791698825075/28578791698825075.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74285,
      "choices": [
        {
          "id": 257387,
          "text": "The hyperglycemia should not be treated because HbA1c is not a reliable indicator of glucose in the setting of kidney failure, and the patient is otherwise in good condition."
        },
        {
          "id": 257388,
          "text": "The use of erythropoietin and the reduced RBC lifespan seen in kidney failure causes HbA1c to overestimate glucose."
        },
        {
          "id": 257389,
          "text": "Treatment with insulin should be considered to achieve a reduction in HbA1c and reduce mortality risk."
        },
        {
          "id": 257390,
          "text": "All the above"
        }
      ],
      "text": "A 62-year-old male is on chronic hemodialysis because of kidney failure attributed to type 2 diabetes. Blood pressure is 150/82 mm Hg, serum creatinine 3.9 mg/dl, Hb is 11.5 g/dL, and HbA1c is 9.5%. He is not being treated with any hypoglycaemic medicines. The patient takes a statin and erythropoietin. He has a good nutritional status. Which of the following statements is true?",
      "unique_key": "Q8224819",
      "question_audio": null,
      "question_video": null,
      "map_id": 34419921,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Treatment with insulin should be considered to achieve a reduction in HbA1c and reduce mortality risk. Explanation: This 62-year-old male with chronic kidney failure due to type 2 diabetes presents with hyperglycemia (HbA1c 9.5%), which is an important risk factor for poor outcomes in patients with kidney disease. Tight glucose control, particularly with insulin, has been shown to improve outcomes in individuals with diabetes, including reducing the risk of complications such as cardiovascular events and progression of kidney disease. In the setting of kidney failure, insulin therapy is a safe and effective option to control blood glucose because insulin is not metabolized by the kidneys, and insulin can be dosed appropriately to achieve target glucose levels. Treating hyperglycemia in patients on hemodialysis is important for improving long-term outcomes and reducing the risk of diabetes-related complications. Therefore, insulin therapy is a reasonable and beneficial treatment option. Incorrect Responses: A. The hyperglycemia should not be treated because HbA1c is not a reliable indicator of glucose in the setting of kidney failure, and the patient is otherwise in good condition. This option is incorrect because while it is true that HbA1c may be less reliable in patients with kidney failure, it still provides valuable information regarding long-term glucose control. Even in the setting of chronic kidney disease (CKD), hyperglycemia should still be addressed to prevent complications like cardiovascular disease, diabetic retinopathy, and neuropathy. In fact, even if HbA1c is less accurate, hyperglycemia itself remains a modifiable risk factor for adverse outcomes, which justifies treatment. B. The use of erythropoietin and the reduced RBC lifespan seen in kidney failure causes HbA1c to overestimate glucose. This option is partially correct in that erythropoietin therapy and shortened red blood cell (RBC) lifespan can affect the accuracy of HbA1c measurements. However, the overestimation of glucose is not the primary concern in this case. While it is true that patients with kidney failure may have false elevations in HbA1c due to reduced RBC lifespan and the effects of erythropoietin, HbA1c is still a useful marker for chronic glycemic control. Even with these limitations, addressing hyperglycemia is important, as long as other factors (such as HbA1c accuracy) are considered when interpreting results. D. All the above This option is incorrect because, as explained above, while HbA1c may be less reliable in kidney disease, it does not mean that hyperglycemia should be left untreated. The correct approach involves insulin therapy to manage blood glucose and improve outcomes in this patient, making option C the most appropriate choice.",
      "correct_choice_id": 257389,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21208941698825088/21208941698825088.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21208941698825088/21208941698825088.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74286,
      "choices": [
        {
          "id": 257391,
          "text": "Start allopurinol"
        },
        {
          "id": 257392,
          "text": "Stop amlodipine as it increases serum uric acid"
        },
        {
          "id": 257393,
          "text": "Start colchicine"
        },
        {
          "id": 257394,
          "text": "All the above"
        }
      ],
      "text": "A 35-year-old male with type 1 diabetes, hypertension and established CKD comes to OPD for routine check-up. He is on insulin, amlodipine and losartan. BP is 120/80 mmHg.Hba1c is 6.9 %, serum creatinine 2.0 mg/dl and serum uric acid 9.2 mg/dl. His urinary sediment is unremarkable and his urine ACR(albumin creatinine ratio) is 400 mg/g. Which of the following are true about his management",
      "unique_key": "Q9519880",
      "question_audio": null,
      "question_video": null,
      "map_id": 34400043,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Start allopurinol Explanation: This 35-year-old male with type 1 diabetes, hypertension, and chronic kidney disease (CKD) has an elevated serum uric acid level of 9.2 mg/dL, which suggests hyperuricemia. The patient also has albuminuria (ACR of 400 mg/g), which is a sign of early diabetic nephropathy. Hyperuricemia is common in patients with CKD and may contribute to worsening kidney function, as elevated uric acid can promote tubulointerstitial fibrosis and glomerulosclerosis. Starting allopurinol, a xanthine oxidase inhibitor, is appropriate in managing hyperuricemia in this patient. Allopurinol lowers serum uric acid levels and may help prevent further kidney damage, particularly in patients with CKD. It is generally well-tolerated and can reduce the risk of uric acid nephropathy, which is important in patients with underlying kidney disease. Incorrect Responses: B. Stop amlodipine as it increases serum uric acid This statement is incorrect because amlodipine, a calcium channel blocker, is not typically associated with a significant increase in serum uric acid levels. In fact, amlodipine is considered a neutral agent regarding uric acid levels, and its use in this patient for hypertension is appropriate. The focus should instead be on managing hyperuricemia directly through medications like allopurinol, rather than discontinuing amlodipine. C. Start colchicine While colchicine is useful in treating acute gout attacks and preventing inflammation, it is not appropriate for chronic management of hyperuricemia or preventing uric acid nephropathy in this case. Allopurinol is the preferred treatment to lower serum uric acid and prevent kidney damage in patients with hyperuricemia and CKD, rather than using colchicine for chronic management. Colchicine is generally used for flare-ups of gout but does not lower uric acid levels in the long term. D. All the above Since B (stopping amlodipine) and C (starting colchicine) are incorrect, D. All the above is not the correct answer. The correct choice is A, which recommends starting allopurinol.",
      "correct_choice_id": 257391,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56549031698825139/56549031698825139.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56549031698825139/56549031698825139.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}